Skip to main content

Neumora Therapeutics, Inc.

corporate_fare Company Profile

Neumora Therapeutics, Inc.

NMRA·NASDAQ·Life Sciences·CIK 0001885522

Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies with brain-penetrant chemistry. The company's therapeutic pipeline targets a range of underserved, prevalent diseases, including neurodegenerative diseases, neuropsychiatric diseases, and metabolic disorders. Neumora is advancing a Phase 3 program for navacaprant, a once-daily oral kappa opioid receptor ("KOR") antagonist, for the treatment of major depressive disorder ("MDD"). Additionally, the company is developing NMRA-511, a highly selective antagonist of the vasopressin 1a receptor ("V1aR"), for the treatment of agitation associated with dementia due to Alzheimer's disease ("AD"). Neumora's pipeline also includes NMRA-898, a novel M4 PAM for the treatment of schizophrenia, and NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor for the treatment of obesity. The company expects to report Phase 3 KOASTAL-2 and -3 topline data in the second quarter of 2026, MAD extension data with NMRA-511 in the second half of 2026, and multiple ascending dose ("MAD") data with NMRA-898 in the second half of 2026. Neumora has scaled its pipeline through internal discovery and business development activities.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for NMRA spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Neumora 10-Q Confirms Going-Concern Doubt on $85.7M Cash
  • Neumora Q3: $85.7M Cash, No Runway Guidance, NMRA-215 IND Filed
  • Neumora Posts $34.4M Q3 Loss, $85.7M Cash, Skips Runway Guidance
  • Neumora Gets Nasdaq Bid-Price Deficiency Notice, 180 Days to Reach $1.00
  • Neumora Flags Going Concern Doubt as Cash Runs Short

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$236.93M
Diluted EPS
-$1.45
Op. Cash Flow
-$206.44M
Operating Income
-$241.16M
Cash & Equivalents
$182.53M
Total Debt
$54.53M
Debt / Equity
0.52×
Shares Outstanding
174.26M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-130388

Short Interest & Short Volume

5.12 days to cover

FINRA reported short interest of 7,006,355 shares in NMRA as of the October 30, 2026 settlement, a 24.2% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 73.4% of NMRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,006,355 shares as of October 30, 2026
Change vs prior period▲ 24.2%
Days to cover5.12 at avg daily volume of 1,368,708
Daily short volume (FINRA facilities)73.4% of 513,669 shares on November 20, 2026
5-day average short volume67.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$0.32 -4.16% today
52-week range · as of 2026-11-16 $0.3154 – $3.65
Market cap
$63.01M
Volume
1.1M (0.6× avg)
3-mo avg 1.8M
Live data · 2026-11-22 04:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NMRA - Latest Insights

NMRA
Nov 16, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4206
Real-time Price: $0.320 info
Change: -$0.1006 (-24%) info
Market Cap: $63.005M info
NMRA
Nov 16, 2026, 8:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4206
Real-time Price: $0.320 info
Change: -$0.1006 (-24%) info
Market Cap: $63.005M info
NMRA
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4206
Real-time Price: $0.320 info
Change: -$0.1006 (-24%) info
Market Cap: $63.005M info
NMRA
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3672
Real-time Price: $0.320 info
Change: -$0.0472 (-13%) info
Market Cap: $63.005M info
NMRA
Aug 14, 2026, 7:23 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.65
Real-time Price: $0.320 info
Change: -$1.33 (-81%) info
Market Cap: $63.005M info
NMRA
Aug 14, 2026, 7:13 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.320 info
Change: -$1.33 (-81%) info
Market Cap: $63.005M info
NMRA
Aug 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.320 info
Change: -$1.33 (-81%) info
Market Cap: $63.005M info
NMRA
Jul 27, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.320 info
Change: -$1.20 (-79%) info
Market Cap: $63.005M info
NMRA
Jun 16, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.9185
Real-time Price: $0.320 info
Change: -$0.5985 (-65%) info
Market Cap: $63.005M info
NMRA
Jun 15, 2026, 8:23 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $0.320 info
Change: -$1.46 (-82%) info
Market Cap: $63.005M info
NMRA
Jun 15, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $0.320 info
Change: -$1.46 (-82%) info
Market Cap: $63.005M info
NMRA
Jun 15, 2026, 8:04 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $0.320 info
Change: -$1.46 (-82%) info
Market Cap: $63.005M info
NMRA
May 07, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $0.320 info
Change: -$1.62 (-84%) info
Market Cap: $63.005M info
NMRA
May 07, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.39
Real-time Price: $0.320 info
Change: -$2.07 (-87%) info
Market Cap: $63.005M info
NMRA
May 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.39
Real-time Price: $0.320 info
Change: -$2.07 (-87%) info
Market Cap: $63.005M info
NMRA
Apr 17, 2026, 4:04 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $0.320 info
Change: -$1.83 (-85%) info
Market Cap: $63.005M info
NMRA
Mar 30, 2026, 7:07 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $2.29
Real-time Price: $0.320 info
Change: -$1.97 (-86%) info
Market Cap: $63.005M info
NMRA
Mar 30, 2026, 6:58 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.33
Real-time Price: $0.320 info
Change: -$2.01 (-86%) info
Market Cap: $63.005M info
NMRA
Mar 30, 2026, 6:53 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $0.320 info
Change: -$2.01 (-86%) info
Market Cap: $63.005M info
NMRA
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $0.320 info
Change: -$1.89 (-86%) info
Market Cap: $63.005M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets